(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.20%) $79.11
(-0.44%) $2.03
(0.02%) $2 310.00
(0.13%) $26.87
(0.16%) $964.10
(-0.01%) $0.932
(-0.03%) $10.99
(-0.03%) $0.798
(-0.02%) $91.11
@ $5.09
发出时间: 14 Feb 2024 @ 22:30
回报率: -13.36%
上一信号: Feb 13 - 02:37
上一信号:
回报率: -0.97 %
Live Chart Being Loaded With Signals
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS)...
Stats | |
---|---|
今日成交量 | 317 012 |
平均成交量 | 263 427 |
市值 | 119.18M |
EPS | $0 ( 2024-02-13 ) |
下一个收益日期 | ( $-0.340 ) 2024-06-26 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.490 |
ATR14 | $0.0110 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Rotunno Mary L. | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Gin Jerry B | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Fitzpatrick Margaret M | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Curley Joanne | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Cunningham Ann Michelle | Buy | 12 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.65 |
Last 94 transactions |
Buy: 11 348 392 | Sell: 716 774 |
音量 相关性
VistaGen Therapeutics Inc 相关性
10 最负相关 | |
---|---|
FEYE | -0.808 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
VistaGen Therapeutics Inc 相关性 - 货币/商品
VistaGen Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $-227 300 |
毛利润: | $-737 100 (324.29 %) |
EPS: | $-8.51 |
FY | 2023 |
营收: | $-227 300 |
毛利润: | $-737 100 (324.29 %) |
EPS: | $-8.51 |
FY | 2022 |
营收: | $1.11M |
毛利润: | $293 700 (26.49 %) |
EPS: | $-7.24 |
FY | 2021 |
营收: | $1.09M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.208 |
Financial Reports:
No articles found.
VistaGen Therapeutics Inc
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。